New research proves that MIMEDX Purion® processed dehydrated human amniotic membrane/chorion has the potential to regulate pathological scar tissue formation

[ad_1]

The proposed mechanism suggests a potential way to improve the results of clinical applications, in which the regulation of excessive fibrosis can promote a normal healing response

The complex nature of MIMEDX dHACM may prove useful in many applications where normal healing is impaired

Marietta, Georgia, June 15, 2021 (Global News Agency) – MiMedx Group, Inc. (NASDAQ:MDXG) (“MIMEDX” or “Company”), using amniotic membrane tissue as the industry leader in regenerative medicine platforms, today announced the publication of its peer-reviewed Learn In the Journal of Research Dermatology (JID) innovation, the potential benefits of dehydrated human amniotic membrane/chorionic membrane (dHACM) treated by MIMEDX Purion were explored to combat complications caused by excessive fibrosis, which is a lot of serious unsatisfactory medical treatment The core pathological process of demand. It is estimated that more than 100 million people worldwide suffer from pathological scar formation each year, including hypertrophic and keloid scar formation. The severity of its long-term effects range from minor cosmetic defects to severe damage to tissue structures and functions in a variety of diseases. Damaged.

DHACM processed by MIMEDX Purion has been widely used to treat a variety of acute and chronic diseases, from diabetic foot ulcers and severe burns to musculoskeletal and sports medicine applications. Clinical evidence shows that the use of these products in the treatment plan can not only accelerate healing, but also improve the quality of repair, which can be demonstrated by reducing scar tissue formation. For a long time, amniotic membrane has been considered to have anti-scarring properties. However, the mechanism to achieve the response is not yet fully understood. Therefore, this study written by Dr. Sarah Moreno, Michelle Massee, and Thomas J. Koob aims to explore the potential mechanism of dHACM’s influence on the fibrotic pathway.

“The clinical severity of the long-term effects of excessive fibrosis or scarring can range from minor cosmetic defects to significantly impaired tissue structure and function. Although many different factors can trigger progressive fibrotic diseases, all fibrosis The common feature of the disease is Sarah E. Moreno, the lead author and research manager of MIMEDX activation, said: “Myofibroblasts that produce extracellular matrix (ECM) are the key mediator of fibrotic tissue remodeling. “We know that the continued presence of pro-fibrotic stimuli can hinder the normal healing process and lead to excessive fibrosis. Our goal is to check whether and how MIMEDX amniotic membrane disrupts this process. This research is the question of the way to answer this question. ”

One in vitro The fibrosis model was developed by stimulating human dermal fibroblasts with transforming growth factor β (TGF-β1) (a pro-fibrotic cytokine) to induce differentiation into myofibroblasts. The phenotypic shift is confirmed by the concomitant expression of α smooth muscle actin (αSMA) and increased extracellular matrix deposition. Although this is a necessary step in the normal healing cascade, long-term continuous stimulation of TGF-β1 will lead to the continuous up-regulation of the fibrotic pathway and eventually lead to pathological scar formation.Therefore, the model evaluates the potential of dHACM treatment in the presence of TGF-β1 as a means to best generalize the environment in vitroThe introduction of dHACM into this model leads to the interruption of the TGF-β1 signaling pathway, reduces the increase in the expression of fibrotic factors and ECM components, and effectively regulates the activity of myofibroblasts.The functional results of these effects are also one In vitro A cell contraction model, in which dHACM treatment reduces the contractile ability of stimulated fibroblasts embedded in a collagen matrix to near the basal level. The data proves the ability of dHACM to regulate intrinsic molecular pathways and suggests a possible mechanism of action for preventing or treating pathological scar formation. Additional data or related animal models are needed to confirm these findings and translate the efficacy into clinical results.

Timothy R. Wright, CEO of MIMEDX, commented: “The amniotic membrane tissue processed by Purion has great potential. We are investing heavily in research and development to improve our scientific understanding of its capabilities and promote its use in debilitated patients. The use of diseases in treatment algorithms. The company’s early work has characterized the core features of our technology, including the identification of more than 300 regulatory proteins and basic biological functions such as cell proliferation and migration. We are continuing to understand the complexity of this organization, For example, the pathological scar formation work carried out here is building on our existing peer-reviewed literature library, which provides MIMEDX with key advantages for the future development of new therapies.”

“The data provided by this study clarifies the molecular pathways that dHACM targets to regulate abnormal fibroblast activity in vitroRobert B. Stein, MD, MD, MD, Executive Vice President of Research and Development of MIMEDX said: “The benefits of this discovery may prove to be a major advancement in the treatment of injuries that cause pathological scar formation.” Praise our team for expansion Our contribution to the understanding of placental tissue and their unwavering commitment to evaluating the utility of human placental tissue processed by MIMEDX Purion as a meaningful medicine to promote more effective healing. “

Important warning statement
This press release contains forward-looking statements. Regarding: (i) the potential benefits of dHACM processed with MIMEDX Purion, including the company’s expectation that it can regulate excessive fibrosis and reduce scarring, and (ii) the expectation that the company will develop new therapies in the future, are forward-looking statements. Other forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “plan,” “potential,” “will,” “preliminary,” and similar expressions, and are based on management’s current beliefs and expect.

Forward-looking statements are subject to risks and uncertainties, and the company cautions investors not to rely too much on such statements. Actual results may differ materially from the results stated in the forward-looking statements. Factors that may cause actual results to differ from expectations include: (i) the need for additional data or related animal models to confirm the results of the study and translate the efficacy into clinical results, and (ii) the company may change its plans due to future events and Postpone or change its future research and development plan. The company described additional risks and uncertainties in the risk factors section of its annual report and quarterly report that it recently filed with the US Securities and Exchange Commission. Any forward-looking statements are only issued on the date of this press release, and the company assumes no obligation to update any forward-looking statements.

About MIMEDX

MIMEDX is an industry leader that uses amniotic membrane tissue as a regenerative medicine platform. It develops and sells allogeneic placental tissue grafts. It adopts a patent-protected proprietary process and is suitable for multiple healthcare fields. As a pioneer in placental biologics, we have not only a basic business focused on meeting the needs of patients with acute and chronic non-healing wounds, but also a promising late-stage pipeline aimed at reducing pain and improving function for patients with degenerative musculoskeletal diseases. We start from Extract our products from human placental tissues and use our proprietary methods to process these tissues, including PURION® process. We use current good organization practices, current good manufacturing practices, and terminal sterilization to produce our allografts. MIMEDX has provided more than 2 million allografts through direct and consignment.For more information, please visit www.mimedx.com.

contact:

investor:
Jack Howard
Investor Relations
404.360.5681
jhowarth@mimedx.com

Main logo

[ad_2]

Source link

Recommended For You

About the Author: News Center